Objective Juvenile SLE (jSLE) is an autoimmune disease characterised by the presence of high levels of autoantibodies, ...
Objective Both belimumab and telitacicept are recognised blockers for B lymphocyte activation, both of which have been ...
Original research: Racial differences in clinical trial perceptions among a large, predominantly Black cohort of people with systemic lupus erythematosus in the Southeastern USA (4 January, 2025) ...